Madeleine Armstrong

6 days ago | oncologypipeline.com | Madeleine Armstrong

Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet. AstraZeneca and Daiichi Sankyo’s HER2-targeting ADC Enhertu, which made $3.8bn in 2024, could soon be heading for first-line breast cancer, following positive data presented at ASCO on Monday from the Destiny-Breast09 trial. The study, in HER2-positive disease, found a 44% reduction in the risk of progression or death with Enhertu plus Roche’s Perjeta, versus Perjeta plus Herceptin and chemo.

1 week ago | oncologypipeline.com | Madeleine Armstrong

But camizestrant’s use could depend on uptake of monitoring – for now. AstraZeneca, seeking an earlier use for its oral SERD camizestrant, told ASCO on Sunday how a new paradigm of treating patients who develop the ESR1 mutation during first-line therapy but before progression improves not only progression-free survival but also PFS2, a more relevant real-world endpoint. However, the real test will be overall survival, and these data are still immature.

1 week ago | oncologypipeline.com | Madeleine Armstrong

BioNTech’s DualityBio-originated B7-H3-targeting ADC BNT324 could have a new use, castrate-resistant prostate cancer, although the company is being cautious about taking this indication forward. Late-line mCRPC cohorts from a phase 1 solid tumour trial, reported at ASCO on Sunday, found a confirmed ORR of 31% across two doses – which looks favourable versus other early-stage prostate cancer assets in development, including J&J’s anti-KLK2 T-cell engager pasritamig, presented at the same session.

1 week ago | oncologypipeline.com | Madeleine Armstrong

The company highlights the safety of its KLK2-targeting T-cell engager pasritamig. At last year’s ASCO Johnson & Johnson saw troubling toxicity with a KLK2-targeting radiopharmaceutical project; this year the group moved to showcase a different asset that it believes to be much safer, the anti-KLK2 T-cell engager pasritamig.

1 week ago | oncologypipeline.com | Madeleine Armstrong

In first-line renal cancer, zanzalintinib plus Opdivo has outshone Cabometyx plus Opdivo. Earlier this year Exelixis’s next-generation tyrosine kinase inhibitor zanzalintinib disappointed in colorectal cancer, but now it has shown more promise in first-line renal cancer, ASCO heard on Saturday. Notably, on a cross-trial basis the asset looks more efficacious than Exelixis’s approved TKI Cabometyx, with lower toxicity.